Cancer Vaccine

E. coli expressing listeriolysin O promotes MHC class I antigen presentation

Published in Cancer Weekly, January 14th, 2003

by Maria G. Essig, MS, ELS, senior medical writer - In a murine model, recombinant E. coli that expressed listeriolysin O (LLO) and ovalbumin (OVA) protein was able to deliver an OVA epitope for MHC class I presentation in dendritic cells (DCs).

K. J. Radford and colleagues at Cancer Research UK in Great Britain and Harvard Medical School in the U.S. engineered E. coli to express both LLO and OVA cytoplastic proteins. In murine dendritic cells, the recombinant E. coli delivered the OVA K^b-restricted epitope SIINFEKL for MHC class I presentation. However, delivery of the OVA 323-339 I-A^b-restricted epitope for MHC class II...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry